ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that an abstract presented at ESMO Asia 2017 on data from its Phase 2 clinical trial of varlitinib in metastatic HER2-positive breast cancer (HER2+ MBC) patients won the Best Poster Award in the breast cancer, metastatic category.

For more information, please refer to the English or Chinese press release.